Clearstead Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $92K | Buy |
732
+376
| +106% | +$47.3K | ﹤0.01% | 1086 |
|
|
2025
Q1 | $39.4K | Buy |
356
+43
| +14% | +$4.76K | ﹤0.01% | 1228 |
|
|
2024
Q4 | $42.7K | Buy |
313
+5
| +2% | +$683 | ﹤0.01% | 1200 |
|
|
2024
Q3 | $35.5K | Sell |
308
-440
| -59% | -$50.7K | ﹤0.01% | 1279 |
|
|
2024
Q2 | $103K | Buy |
748
+285
| +62% | +$39.2K | ﹤0.01% | 991 |
|
|
2024
Q1 | $63K | Sell |
463
-45
| -9% | -$6.13K | ﹤0.01% | 712 |
|
|
2023
Q4 | $66.9K | Sell |
508
-552
| -52% | -$72.7K | ﹤0.01% | 673 |
|
|
2023
Q3 | $119K | Buy |
1,060
+583
| +122% | +$65.6K | ﹤0.01% | 683 |
|
|
2023
Q2 | $45K | Buy |
477
+247
| +107% | +$23.3K | ﹤0.01% | 747 |
|
|
2023
Q1 | $23.3K | Buy |
+230
| New | +$23.3K | ﹤0.01% | 820 |
|